Skip to content
Patients
HCPs
X-twitter Instagram Youtube Icon-mail Tiktok
Follow on X
Home
Daily Updates

Categories

Efficacy and toxicity of post-neoadjuvant trastuzumab emtansine in HER2-positive breast cancer patients treated at Institut Curie Hospitals.

  • Post category:Breast Cancer
  • Reading time:1 min read

This retrospective bicentric cohort study evaluated the real-world efficacy and safety of adjuvant trastuzumab emtansine...

Continue ReadingEfficacy and toxicity of post-neoadjuvant trastuzumab emtansine in HER2-positive breast cancer patients treated at Institut Curie Hospitals.

Real-world outcomes of trastuzumab deruxtecan in HR-negative HER2-low metastatic breast cancer.

  • Post category:Breast Cancer
  • Reading time:1 min read

This multicenter real-world study assessed trastuzumab deruxtecan (T-DXd) in 64 patients with HR-negative, HER2-low meta...

Continue ReadingReal-world outcomes of trastuzumab deruxtecan in HR-negative HER2-low metastatic breast cancer.

Genomic tests to guide management of breast cancer in Europe: regulation, reimbursement, adoption, and challenges.

  • Post category:Breast Cancer
  • Reading time:1 min read

This publication reviews the integration of genomic tests, specifically the Oncotype DX Breast Recurrence Score® test,...

Continue ReadingGenomic tests to guide management of breast cancer in Europe: regulation, reimbursement, adoption, and challenges.

Rewriting the radiation playbook: NSABP B-51 and the rise of pathologic precision.

  • Post category:Breast Cancer
  • Reading time:1 min read

The NSABP B-51/RTOG 1304 trial demonstrates that breast cancer patients who achieve nodal clearance following neoadjuvan...

Continue ReadingRewriting the radiation playbook: NSABP B-51 and the rise of pathologic precision.

Prognostic and predictive significance of neutrophil/lymphocyte ratio for trastuzumab treatment efficacy in HER2-positive breast cancer.

  • Post category:Breast Cancer
  • Reading time:1 min read

This study analyzed 843 patients with HER2-positive breast cancer to evaluate the prognostic and predictive value of bas...

Continue ReadingPrognostic and predictive significance of neutrophil/lymphocyte ratio for trastuzumab treatment efficacy in HER2-positive breast cancer.

The estimated long-term clinical effects of BRCA testing and olaparib treatment of early breast cancer in the US population: a population impact model.

  • Post category:Breast Cancer
  • Reading time:1 min read

This study developed a decision-analytic model to evaluate the long-term impact of widespread germline BRCA testing and...

Continue ReadingThe estimated long-term clinical effects of BRCA testing and olaparib treatment of early breast cancer in the US population: a population impact model.
  • © Together4Cancer. All rights reserved.
  • Privacy Policy
  • Terms of Use